Ortomeda - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 96,400 | 111,294 | 86,817 | 76,759 | 80,693 | 80,963 | 88,402 | 96,465 |
| Profit before tax | 3,913 | 9,192 | 2,880 | - | -2,657 | -2,490 | -5,434 | -3,018 |
| Net profit | 3,326 | 7,813 | 2,736 | -12,270 | -2,657 | -2,490 | -5,434 | -3,018 |
| Equity | 5,098 | 12,911 | 15,647 | 3,377 | 239 | -646 | -6,080 | -9,098 |
| Liabilities | 13,959 | 12,464 | 12,750 | 10,699 | 15,979 | 17,703 | 22,077 | 29,508 |
| Non-current assets | 8,143 | 10,108 | 10,251 | 8,201 | 7,720 | 7,521 | 7,521 | 12,321 |
| Current assets | 10,914 | 15,267 | 18,146 | 5,875 | 8,498 | 9,536 | 8,476 | 8,089 |
| Total assets | 19,057 | 25,375 | 28,397 | 14,076 | 16,218 | 17,057 | 15,997 | 20,410 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 11,584 | 11,854 | 9,896 |
| Social insurance contributions | - | - | - | - | - | 15,086 | 17,297 | 15,207 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +18.4% | +15.5% | -22.0% | -11.6% | +5.1% | +0.3% | +9.2% | +9.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 17.5% | 30.8% | 9.6% | -87.2% | -16.4% | -14.6% | -34.0% | -14.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 65.2% | 60.5% | 17.5% | -363.3% | -1111.7% | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 3.5% | 7.0% | 3.2% | -16.0% | -3.3% | -3.1% | -6.1% | -3.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 4.1% | 8.3% | 3.3% | - | -3.3% | -3.1% | -6.1% | -3.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.7 | 1.0 | 0.8 | 3.2 | 66.9 | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 9,254 | 11,129 | 8,334 | 8,451 | 10,087 | 10,120 | 11,050 | 12,058 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Ortomeda - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-19 | 2026-08-19 | 1615.55 |
| 2026-08-16 | 2026-08-17 | 0.66 |
| 2026-07-23 | 2026-08-14 | 0.66 |
| 2026-07-16 | 2026-07-17 | 1571.06 |
| 2026-06-16 | 2026-06-17 | 809.58 |
| 2025-05-04 | 2025-05-07 | 0.31 |
| 2025-04-24 | 2025-04-29 | 0.31 |
| 2023-05-16 | 2023-05-16 | 1834.81 |
| 2022-09-16 | 2022-09-18 | 1249.87 |
Ortomeda - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Ortomeda is: 13 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-01 | 2026-09-02 | 12.71 |
| 2026-08-16 | 2026-08-31 | 12.03 |
| 2026-08-13 | 2026-08-15 | 2405.42 |
| 2026-08-05 | 2026-08-12 | 2393.39 |
| 2026-08-02 | 2026-08-04 | 1183.36 |
| 2026-07-03 | 2026-08-01 | 1169.1 |
| 2026-06-26 | 2026-07-02 | 9.6 |
| 2026-06-05 | 2026-06-25 | 1124.64 |
| 2026-06-01 | 2026-06-02 | 12.92 |
| 2026-05-31 | 2026-05-31 | 9.0 |
| 2026-05-15 | 2026-05-30 | 4.95 |
| 2026-05-08 | 2026-05-14 | 1041.81 |
| 2026-04-11 | 2026-05-07 | 4.95 |
| 2025-05-09 | 2025-05-13 | 726.69 |
| 2025-05-01 | 2025-05-08 | 5.76 |
| 2025-04-30 | 2025-04-30 | 3.36 |
| 2025-04-02 | 2025-04-10 | 7.68 |
| 2025-03-31 | 2025-04-01 | 2.64 |
| 2025-03-07 | 2025-03-20 | 876.87 |
| 2025-02-28 | 2025-02-28 | 76.7 |
| 2025-02-14 | 2025-02-27 | 72.02 |
| 2025-01-03 | 2025-01-23 | 4.94 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Ortomeda, UAB (code 300129432) is a Private Limited Liability Company engaged in medical specialists activities. In 2025, the company generated revenue of EUR 96.5K, up 9.1% year on year and 19.1% over two years, showing a steady upward sales trend. Profitability remained weak: net loss was EUR 3.0K in 2025, after losses of EUR 5.4K in 2024 and EUR 2.5K in 2023. The profit margin in 2025 was -3.1%, broadly in line with the prior year’s level, while the business continued to operate below break-even. The balance sheet remained pressured, with total assets of EUR 20.4K, liabilities of EUR 29.5K and negative equity of EUR 9.1K at the end of 2025. Long-term assets increased to EUR 12.3K, while short-term assets were EUR 8.1K. Asset turnover stood at 4.73x, indicating relatively high revenue generation from a modest asset base. Revenue per employee was EUR 12.1K, and profit per employee was negative.